The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis
| dc.contributor.author | Evangelista, Karine Cavalcanti Maurício de Sena | |
| dc.contributor.author | Dias, Paula Cristina Silveira | |
| dc.contributor.author | Paiva, Maria Sanali Moura de Oliveira | |
| dc.contributor.author | Ferreira, Diana Quitéria Cabral | |
| dc.contributor.author | Ururahy, Marcela Abbott Galvão | |
| dc.contributor.author | Rezende, Adriana Augusto | |
| dc.contributor.author | Abdalla, Dulcinéia Saes Parra | |
| dc.contributor.author | Pedrosa, Lucia Fatima Campos | |
| dc.date.accessioned | 2024-08-26T23:12:14Z | |
| dc.date.available | 2024-08-26T23:12:14Z | |
| dc.date.issued | 2014-04 | |
| dc.description.resumo | Background: Statins have multiple antiatherosclerotic effects, but can reduce blood plasma concentrations of minerals, including zinc. As zinc possesses antiinflammatory and antioxidant effects, low zinc status can promote injuries or inadequate tissue repair in endothelial cells. Metallothionein (MT) expression might modulate responses induced by statins in patients with atherosclerosis. However, research regarding mineral status and the use of statins is scarce. This study evaluated the effects of zinc supplementation on zinc status and expression of the zinc-dependent MT1F and MT2A genes in patients with atherosclerosis treated with rosuvastatin. Methods: A double-blind, randomized clinical trial was performed with 54 participants treated with 10 mg rosuvastatin for 4 months with or without zinc supplementation (30 mg/day). Diet, lipid profile, high-sensitivity reactive protein C (hs-CRP), plasma and erythrocyte zinc concentrations, erythrocyte superoxide dismutase (SOD) activity, and MT1F and MT2A genes expression were analyzed before and after intervention. Results: Rosuvastatin therapy was effective in reducing low- and non-high-density lipoprotein, total cholesterol, triglycerides, and hs-CRP levels, independent of zinc supplementation. Additionally, zinc treatment had no effect on SOD enzyme activity (P = 0.201), plasma (P > 0.671) and erythrocyte (P > 0.123) zinc concentrations, or the pattern of MT1F and MT2A genes expression (P = 0.088 and P = 0.229, respectively). Conclusions: The effectiveness of rosuvastatin treatment is independent of the effects of zinc supplementation. Moreover, rosuvastatin treatment did not have a significant impact on zinc status or MT1F and MT2A genes expression in patients with atherosclerosis | pt_BR |
| dc.identifier.citation | DIAS, Paula Cristina Silveira; EVANGELISTA, Karine Cavalcanti Mauricio Sena; PAIVA, Maria Sanali Moura de Oliveira; FERREIRA, Diana Quitéria Cabral; URURAHY, Marcela Abbott Galvão; REZENDE, Adriana Augusto; ABDALLA, Dulcinéia Saes Parra; PEDROSA, Lucia Fatima Campos. The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis. Journal of Trace Elements in Medicine and Biology, [S.l.], v. 28, n. 2, p. 194-199, abr. 2014. DOI: 10.1016/j.jtemb.2014.01.003. Disponível em: https://www.sciencedirect.com/science/article/pii/S0946672X14000066?via%3Dihub. Acesso em: 26 jul. 2024. | pt_BR |
| dc.identifier.doi | http://dx.doi.org/10.1016/j.jtemb.2014.01.003 | |
| dc.identifier.uri | https://repositorio.ufrn.br/handle/123456789/59901 | |
| dc.language | en | pt_BR |
| dc.publisher | Journal of Trace Elements in Medicine and Biology | pt_BR |
| dc.subject | Atherosclerosis | pt_BR |
| dc.subject | Metallothionein | pt_BR |
| dc.subject | Rosuvastatin | pt_BR |
| dc.subject | Zinc supplementation | pt_BR |
| dc.title | The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis | pt_BR |
| dc.type | article | pt_BR |
Arquivos
Licença do Pacote
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.45 KB
- Formato:
- Item-specific license agreed upon to submission
Nenhuma Miniatura disponível